Mestranol/noretynodrel
Norethynodrel Progestogen | | |
Clinical data | ||
---|---|---|
Trade names | Enavid, Enovid | |
Routes of administration | By mouth | |
ATC code | ||
Legal status | ||
Legal status |
| |
Identifiers | ||
CAS Number | ||
PubChem CID | ||
CompTox Dashboard (EPA) |
Mestranol/norethynodrel was the first
Medical uses
Mestranol/noretynodrel was indicated in the treatment of
Available forms
The medication contained 0.15 mg mestranol and 10 mg noretynodrel.[8] Additional formulations containing 0.075 mg mestranol and 5 mg noretynodrel as well as 0.1 mg mestranol and 2.5 mg noretynodrel were subsequently introduced.[8] One formulation also contained 0.075 mg mestranol and 3 mg noretynodrel.[8]
History
Creation
Enovid was first manufactured when scientists isolated progesterone from diosgenin, then removed 19-carbon from the molecule. This new form of progesterone had higher progestational activity, which prevented pregnancy.[11]
Social impact
Initially sold in 1957, Enovid was first marketed as a treatment for gynecological disorders. In 1960, its sale as an oral contraceptive was approved by the FDA. This was seen as a major improvement to contraceptives as a whole, being preferred over other methods such as condoms and diaphragms.[12]
Complications and legal proceedings
The first published case report of a
Enovid was discontinued in the U.S. in 1988, along with other first-generation high-estrogen COCPs.[22][23]
See also
References
- ^ Junod SW (1998). "FDA's Approval of the First Oral Contraceptive, Enovid". Histories of Product Regulation. Update (bimonthly publication of the Food and Drug Law Institute). U.S. Food and Drug Administration. Archived from the original on 14 January 2012.
- ^ "FDA Approved Drug Products". FDA.
- ^ PMID 11995593.
- ISBN 0-8090-3817-X.
- ISBN 0-8018-5876-3.
- PMID 20789252.
- PMC 1970195.
- ^ ISBN 978-0-300-16791-7.
- ISBN 978-0-323-15726-1.
- ISBN 978-0-203-31939-0.
- PMID 36243109.
- PMID 11995593. Retrieved 2023-11-29.
- PMID 14261427.
- .
- ^ ISBN 0-300-08943-0.
- ISBN 0-385-14575-6.
- ^ ISBN 0-8018-5876-3.
- ^ FDA (June 11, 1970). "Statement of policy concerning oral contraceptive labeling directed to users". Federal Register. 35 (113): 9001–9003.
- ^ FDA (January 31, 1978). "Oral contraceptives; requirement for labeling directed to the patient". Federal Register. 43 (21): 4313–4334.
- ^ FDA (May 25, 1989). "Oral contraceptives; patient package insert requirement". Federal Register. 54 (100): 22585–22588.
- ISBN 0-7817-6488-2.
- ^ "Searle, 2 others to stop making high-estrogen pill". St. Louis Post-Dispatch. Reuters News Service. 1988-04-15. pp. 7D. Retrieved 2009-08-29.
- ^ "High-estrogen 'pill' going off market". San Jose Mercury News. 1988-04-15. Retrieved 2009-08-29.
Further reading
- Snider S. "The Pill: 30 Years of Safety Concerns". OCLC 25936326.